ALIAS2 Study Site
About the ALIAS2 trial

Welcome to the ALIAS2 study site!

The ALIAS2 study is a Phase III Randomized Multicenter clinical trial.
This study is conducted to ascertain whether high-dose human albumin therapy confers neuroprotection in acute ischemic stroke.


The ALIAS2 trial is supported with a web-based clinical trial data management system, WebDCU™.

To enter the WebDCU™ data management system, click on the button below.
A user ID and password are required to access this system.

Powered by Privacy & Disclaimer
© Copyright 2006 - 2014 Medical University of South Carolina. All rights reserved.